Stuart A. Aaronson

63.4k total citations · 18 hit papers
438 papers, 45.8k citations indexed

About

Stuart A. Aaronson is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Stuart A. Aaronson has authored 438 papers receiving a total of 45.8k indexed citations (citations by other indexed papers that have themselves been cited), including 274 papers in Molecular Biology, 162 papers in Genetics and 107 papers in Oncology. Recurrent topics in Stuart A. Aaronson's work include Virus-based gene therapy research (143 papers), Animal Virus Infections Studies (72 papers) and Cancer-related Molecular Pathways (54 papers). Stuart A. Aaronson is often cited by papers focused on Virus-based gene therapy research (143 papers), Animal Virus Infections Studies (72 papers) and Cancer-related Molecular Pathways (54 papers). Stuart A. Aaronson collaborates with scholars based in United States, Italy and Japan. Stuart A. Aaronson's co-authors include George J. Todaro, John Stephenson, Jeffrey S. Rubin, Steven R. Tronick, Keith C. Robbins, Donald P. Bottaro, Matthias H. Kraus, Jacalyn H. Pierce, Paul W. Finch and C. Richter King and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Stuart A. Aaronson

433 papers receiving 42.3k citations

Hit Papers

Identification of the Hepatocyte Growth Factor Recep... 1968 2026 1987 2006 1991 1973 1991 1983 1982 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
    1991 1.9k citations Andrew M. Chan, Stuart A. Aaronson et al. profile →
  2. In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2
    1973 1.9k citations Stuart A. Aaronson et al. profile →
  3. Growth Factors and Cancer
    1991 1.4k citations Stuart A. Aaronson profile →
  4. Simian Sarcoma Virus onc Gene, v- sis , Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth Factor
    1983 1.2k citations Stuart A. Aaronson et al. profile →
  5. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.
    1982 1.1k citations Steven R. Tronick, Stuart A. Aaronson et al. profile →
  6. Human KGF is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth
    1989 869 citations Stuart A. Aaronson et al. profile →
  7. erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
    1987 864 citations Jacalyn H. Pierce, Stuart A. Aaronson et al. profile →
  8. Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
    1985 855 citations Stuart A. Aaronson et al. profile →
  9. Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis
    2000 751 citations Rui Fang Qiao, Stuart A. Aaronson et al. profile →
  10. Murine Sarcoma and Leukemia Viruses: Assay Using Clonal Lines of Contact-Inhibited Mouse Cells
    1969 739 citations Stuart A. Aaronson et al. profile →
  11. Purification and characterization of a newly identified growth factor specific for epithelial cells.
    1989 739 citations Stuart A. Aaronson et al. profile →
  12. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow
    2001 653 citations Anna Bafico, Guizhong Liu et al. Nature Cell Biology profile →
  13. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
    1987 573 citations Jacalyn H. Pierce, Stuart A. Aaronson et al. profile →
  14. Development of 3T3‐like lines from Balb/c mouse embryo cultures: Transformation susceptibility to SV40
    1968 562 citations Stuart A. Aaronson et al. profile →
  15. Isolation of a Novel Receptor cDNA Establishes the Existence of Two PDGF Receptor Genes
    1989 531 citations Mohammad A. Heidaran, Jacalyn H. Pierce et al. profile →
  16. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes
    1982 502 citations Steven R. Tronick, Stuart A. Aaronson et al. profile →
  17. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells
    1982 433 citations Steven R. Tronick, Stuart A. Aaronson et al. profile →
  18. Induction of Murine C-Type Viruses from Clonal Lines of Virus-Free BALB/3T3 Cells
    1971 362 citations Stuart A. Aaronson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart A. Aaronson United States 107 27.9k 12.2k 9.3k 6.4k 4.5k 438 45.8k
J. Michael Bishop United States 116 33.0k 1.2× 9.5k 0.8× 11.4k 1.2× 5.7k 0.9× 4.5k 1.0× 356 48.6k
Philip Leder United States 124 41.0k 1.5× 11.8k 1.0× 10.5k 1.1× 13.6k 2.1× 6.2k 1.4× 354 63.5k
Mark C. Willingham United States 90 17.6k 0.6× 9.4k 0.8× 3.8k 0.4× 5.5k 0.8× 4.7k 1.0× 425 33.5k
Rik Derynck United States 118 38.9k 1.4× 17.3k 1.4× 5.2k 0.6× 5.6k 0.9× 4.2k 0.9× 211 57.0k
Carl‐Henrik Heldin Sweden 132 41.7k 1.5× 14.1k 1.2× 4.7k 0.5× 5.9k 0.9× 6.7k 1.5× 494 62.7k
George J. Todaro United States 89 16.9k 0.6× 7.6k 0.6× 9.0k 1.0× 4.4k 0.7× 2.1k 0.5× 274 31.9k
Michael D. Waterfield United Kingdom 80 20.8k 0.7× 7.2k 0.6× 3.7k 0.4× 4.3k 0.7× 5.2k 1.2× 187 32.3k
Donald Küfe United States 111 27.8k 1.0× 12.7k 1.0× 3.6k 0.4× 10.0k 1.6× 2.6k 0.6× 621 41.4k
Charles J. Sherr United States 96 39.2k 1.4× 30.4k 2.5× 6.0k 0.6× 6.6k 1.0× 7.6k 1.7× 271 58.0k
Joan S. Brugge United States 111 25.6k 0.9× 10.2k 0.8× 3.9k 0.4× 5.2k 0.8× 9.5k 2.1× 259 41.9k

Countries citing papers authored by Stuart A. Aaronson

Since Specialization
Citations

This map shows the geographic impact of Stuart A. Aaronson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart A. Aaronson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart A. Aaronson more than expected).

Fields of papers citing papers by Stuart A. Aaronson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart A. Aaronson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart A. Aaronson. The network helps show where Stuart A. Aaronson may publish in the future.

Co-authorship network of co-authors of Stuart A. Aaronson

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart A. Aaronson. A scholar is included among the top collaborators of Stuart A. Aaronson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart A. Aaronson. Stuart A. Aaronson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Yitian, Kyeongah Kang, Brian A. Coakley, et al.. (2025). Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4. The EMBO Journal. 44(6). 1866–1883.
2.
Emmett, Matthew J., Christos Adamopoulos, Stuart A. Aaronson, et al.. (2025). RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular Cancer Research. 24(1). 60–71.
3.
Kotini, Andriana G., Elsa Bernard, Davide Esposito, et al.. (2022). Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Advances. 6(10). 2992–3005. 8 indexed citations
4.
Wang, Lin, Yitian Xu, Kyeongah Kang, et al.. (2022). World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates. Cancer Research Communications. 2(6). 518–532. 1 indexed citations
5.
Wu, Xuewei, Xiaobao Yang, Yan Xiong, et al.. (2021). Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer. 2(4). 429–443. 47 indexed citations
6.
Adamopoulos, Christos, Tamer A. Ahmed, Maxwell R. Tucker, et al.. (2021). Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery. 11(7). 1716–1735. 40 indexed citations
7.
Gong, Yixuan, Li Wang, Naomi Alpert, et al.. (2019). Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Molecular Cancer Research. 17(8). 1605–1612. 20 indexed citations
8.
Iomini, Carlo, et al.. (2018). Kinesin-2 and IFT-A act as a complex promoting nuclear localization of β-catenin during Wnt signalling. Nature Communications. 9(1). 5304–5304. 25 indexed citations
9.
Pappas, Kyrie, Jia Xu, Sakellarios Zairis, et al.. (2017). p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Molecular Cancer Research. 15(8). 1051–1062. 48 indexed citations
10.
Schoenfeld, David A., Fang Tian, Hyung-Gu Kim, et al.. (2012). Expression of the p53 Target CDIP Correlates with Sensitivity to TNFα-Induced Apoptosis in Cancer Cells. Cancer Research. 72(9). 2373–2382. 9 indexed citations
11.
Mahale, Alka, Zahid Khan, Makoto Igarashi, et al.. (2008). Clonal Selection in Malignant Transformation of Human Fibroblasts Transduced with Defined Cellular Oncogenes. Cancer Research. 68(5). 1417–1426. 19 indexed citations
12.
Spiegelman, Vladimir S., Weigang Tang, Andrew M. Chan, et al.. (2002). Induction of Homologue of Slimb Ubiquitin Ligase Receptor by Mitogen Signaling. Journal of Biological Chemistry. 277(39). 36624–36630. 41 indexed citations
13.
Bafico, Anna, Guizhong Liu, A. Yaniv, Arnona Gazit, & Stuart A. Aaronson. (2001). Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nature Cell Biology. 3(7). 683–686. 653 indexed citations breakdown →
14.
Kurdistani, Siavash K., et al.. (1998). Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.. PubMed. 58(19). 4439–44. 225 indexed citations
15.
Medina, Sixtina Gil Diez de, Dominique Chopin, Ahmed El Marjou, et al.. (1997). Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 14(3). 323–330. 73 indexed citations
16.
Beeler, John F., William J. LaRochelle, Márcio F. Chedid, Steven R. Tronick, & Stuart A. Aaronson. (1994). Prokaryotic Expression Cloning of a Novel Human Tyrosine Kinase. Molecular and Cellular Biology. 14(2). 982–988. 14 indexed citations
17.
18.
Lacal, Juan Carlos & Stuart A. Aaronson. (1986). Monoclonal Antibody Y13-259 Recognizes an Epitope of the p21 ras Molecule Not Directly Involved in the GTP-Binding Activity of the Protein. Molecular and Cellular Biology. 6(4). 1002–1009. 2 indexed citations
19.
Pierce, Jacalyn H. & Stuart A. Aaronson. (1982). BALB- and Harvey-murine sarcoma virus transformation of a novel lymphoid progenitor cell.. The Journal of Experimental Medicine. 156(3). 873–887. 61 indexed citations
20.
Greenberger, Joel S., John Stephenson, William C. Moloney, & Stuart A. Aaronson. (1975). Different hematological diseases induced by type C viruses chemically activated from embryo cells of different mouse strains.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 35(1). 245–52. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Michael Bishop Breakdown of academic impact, for papers by Philip Leder Breakdown of academic impact, for papers by Mark C. Willingham Breakdown of academic impact, for papers by Rik Derynck Breakdown of academic impact, for papers by Carl‐Henrik Heldin Breakdown of academic impact, for papers by George J. Todaro Breakdown of academic impact, for papers by Michael D. Waterfield Breakdown of academic impact, for papers by Donald Küfe Breakdown of academic impact, for papers by Charles J. Sherr Breakdown of academic impact, for papers by Joan S. Brugge
Rankless by CCL
2026